Clinical Trial Update: Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing SPD485 in children aged 6-12 with attention deficit hyperactivity disorder, focusing on efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPD485

Snippet

Sponsor: Noven Therapeutics | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 2 | Status: COMPLETED